[Effects of paeoniflorin on pathological changes in global brain ischemia model rats].
OBJECTIVE
To explore the effects of paeoniflorin on blood brain barrier and pathological changes in brain ischemia.


METHODS
Mice were divided into sham operation group, model group, positive control group-Deng zhanhua tablet group and three different dose (high, middle, low-dose) groups of paeoniflorin. The neurological symptoms of rats were observed. The SOD of ischemic brain tissue, MDA BBB and EAA contents were determined. The ultrastructure on the brain cells was inspected by transmission electron microscope.


RESULTS
Paeoniflorin had the protetive effects on 4VO model of total cerebral ischemia. Paeoniflorin could obviously increase SOD content, reduce MDA content in rat brain-tissue and alleviate oxidative stress damage by cerebral ischemia on rat brain. Paeoniflorin could improve pathological changes of cell nuclear, perikaryon, mitochondria and myelin sheath, which was the morphologic basis of the protective effect on ischemia. Paeoniflorin could alleviate the incrense of EAA content caused by and hypoxia and inhibit the excitatory neural toxicity by EAA.


CONCLUSIONS
Paeoniflorin has the protection effect on the brain edema after cerebral ischemia, the oxidative stress damage on brain tissue, the ultrastructure lesions of cells and the BBB. The protective mechanism may be related to inhibiting intracellular calcium overload, anti-free radical and reducing EAA content.
Sun
Rong
R
Shandong Academy of Chinese Medicine, Jinan 250014, China. sunrong312@263.net
Yi
Yin-Ping
YP
Lv
Li-Li
LL
Zhang
Zuo-Ping
ZP
Sun
Hu
H
Liu
Guo-Qing
GQ
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001565:Benzoates / Q000302:isolation & purification / Q000494:pharmacology*; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D001921:Brain / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D002545:Brain Ischemia / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D001952:Bridged-Ring Compounds / Q000302:isolation & purification / Q000494:pharmacology*; D005960:Glucosides / Q000302:isolation & purification / Q000494:pharmacology*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008854:Microscopy, Electron; D039821:Monoterpenes; D018696:Neuroprotective Agents / Q000302:isolation & purification / Q000494:pharmacology*; D029596:Paeonia / Q000737:chemistry; D010946:Plants, Medicinal / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000378:metabolism; D006027:Glycosides
D001565:Benzoates; D001952:Bridged-Ring Compounds; D005960:Glucosides; D008315:Malondialdehyde; D039821:Monoterpenes; D018696:Neuroprotective Agents; D013482:Superoxide Dismutase; C015423:peoniflorin; D006027:Glycosides